Atrium Therapeutics earns $15 million milestone payment from Bristol Myers Squibb under cardiovascular collaboration

BMY•2026-08-13

Collaboration terms and future funding

The payment falls under a global licensing and research collaboration covering multiple RNA-based cardiovascular programs.

The agreement includes eligibility for up to about USD 1.35 billion in R&D milestones and up to about USD 825 million in commercial milestones.

Bristol Myers Squibb will fund future clinical development, regulatory filings, and commercialization for programs from the collaboration.

Milestone payment from Bristol Myers Squibb

Atrium Therapeutics earned a USD 15 million milestone payment from Bristol Myers Squibb tied to delivery of a lead cardiovascular compound.

Sources

Atrium Therapeutics earns $15 million milestone payment from Bristol Myers Squibb under cardiovascular collaboration

Publicnow

Atrium Therapeutics earns $15 million milestone payment from Bristol Myers Squibb under cardiovascular collaboration

Collaboration terms and future funding

Milestone payment from Bristol Myers Squibb

Related News

SINTX regains Nasdaq compliance with $2.5 million stockholders’ equity rule

IceCure highlights 5-year ICE3 breast cancer trial showing 3.1% recurrence rate after cryoablation

Goldman Sachs holds 5.15% stake in Alstom

Sources

Atrium Therapeutics earns $15 million milestone payment from Bristol Myers Squibb under cardiovascular collaboration

PepsiCo says 68% of beverage volume meets 2025 added-sugar calorie target in latest ESG update

Avalanche Treasury schedules conference call for Q2 2026 results